TransMedics Group Inc TMDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TMDX is a good fit for your portfolio.
News
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
TransMedics Reports First Quarter 2024 Financial Results
-
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Uber, Datadog stocks gain, Air Products shares lead S&P 500 losers and other stocks on the move
-
TransMedics' stock pops after organ-transplant company's 'blockbuster' third-quarter results
Trading Information
- Previous Close Price
- $135.09
- Day Range
- $133.01–139.96
- 52-Week Range
- $36.42–144.23
- Bid/Ask
- $133.04 / $134.25
- Market Cap
- $4.38 Bil
- Volume/Avg
- 501,258 / 862,586
Key Statistics
- Price/Earnings (Normalized)
- 518.59
- Price/Sales
- 15.07
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Growth
- Total Number of Employees
- 584
- Website
- https://www.transmedics.com
Comparables
Valuation
|
Metric
|
TMDX
|
SWAV
|
NARI
|
|---|---|---|---|
Price/Earnings (Normalized) | 518.59 | 86.15 | 540.94 |
Price/Book Value | 27.83 | 16.70 | 6.53 |
Price/Sales | 15.07 | 16.29 | 5.57 |
Price/Cash Flow | 84.03 | 52.56 | 116.20 |
Price/Earnings
TMDX
SWAV
NARI
Financial Strength
|
Metric
|
TMDX
|
SWAV
|
NARI
|
|---|---|---|---|
Quick Ratio | 8.60 | 12.49 | 2.09 |
Current Ratio | 9.72 | 13.81 | 2.71 |
Interest Coverage | −0.82 | 19.59 | −98.60 |
Quick Ratio
TMDX
SWAV
NARI
Profitability
|
Metric
|
TMDX
|
SWAV
|
NARI
|
|---|---|---|---|
Return on Assets (Normalized) | 1.57% | 18.92% | 2.99% |
Return on Equity (Normalized) | 6.37% | 36.87% | 3.92% |
Return on Invested Capital (Normalized) | 1.80% | 20.45% | 1.60% |
Return on Assets
TMDX
SWAV
NARI
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Sjpwlwgfg | Pfsjgx | $179.6 Bil | |
SYK
| Stryker Corp | Mtmllrbmmg | Xlbb | $131.8 Bil | |
BSX
| Boston Scientific Corp | Hgrflrjq | Jjycfy | $111.6 Bil | |
MDT
| Medtronic PLC | Mqqcgfsk | Wtfjbb | $107.9 Bil | |
EW
| Edwards Lifesciences Corp | Pbtncdlpd | Zjyglsx | $52.5 Bil | |
DXCM
| DexCom Inc | Lxfqbbnxn | Wvqz | $46.8 Bil | |
PHG
| Koninklijke Philips NV ADR | Jsxndhnl | Hybpbrh | $24.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Bhjbspnyk | Zpmg | $23.2 Bil | |
STE
| Steris PLC | Bvzllbpbz | Kqlykj | $22.7 Bil | |
ALGN
| Align Technology Inc | Dmnymlny | Hrtptvw | $19.3 Bil |